Chemours Stock Drops 16.5% After Q4 Results: Analysts See $16 Fair Value

robot
Abstract generation in progress

Chemours (CC) stock dropped 16.5% after reporting Q4 and full-year 2025 earnings, which showed a $47 million net loss and weak profitability, with adjusted EPS of $0.95 missing analyst expectations. The company faced declining revenue, persistent cost pressures, and a high net debt-to-EBITDA ratio of 8.3x, leading to investor concerns despite positive free cash flow. Analysts currently target a $16 fair value for the stock.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin